IP Verse

Variants Of C-Type Natriuretic Peptide

EP3175863

BIOMARIN PHARMACEUTICAL INC.
Application Number
EP16192229A
Filing Date
May 20, 2010
Status
Granted And Under Opposition
Oct 29, 2021
Grant Date
Dec 1, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3175863B1 was granted on Dec 1, 2021 by Biomarin Pharmaceutical Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ASCENDIS PHARMA GROWTH DISORDERS A/SSep 1, 2022ADMISSIBLE

More Opposed Patents of Biomarin Pharmaceutical Inc.

The table below shows the patents of Biomarin Pharmaceutical Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3461503Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringMay 11, 20225
EP3138566Treatment Of Phenylketonuria With Bh4Jan 26, 20223
EP2545939Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringDec 16, 20205

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents